# bioRxiv æŠ•ç¨¿å®Œæ•´æŒ‡å—

**è«–æ–‡æ¨™é¡Œ**: Multi-Dimensional Integrative Analysis of PD-L1 Regulatory Networks: A Computational Framework Integrating Large-Scale Genomics and Immune Deconvolution Across 1,635 Cancer Patients

**æŠ•ç¨¿ç¶²å€**: https://submit.biorxiv.org/

**æº–å‚™æ™‚é–“**: 2025-11-07
**æŠ•ç¨¿æª”æ¡ˆ**: `MANUSCRIPT_bioRxiv_SUBMISSION_FINAL.pdf` (2.7 MB, 34 pages)

---

## ğŸ“‹ æŠ•ç¨¿å‰æª¢æŸ¥æ¸…å–®

### âœ… å¿…å‚™æ–‡ä»¶
- [x] ä¸»è¦ç¨¿ä»¶ PDFï¼ˆå·²æº–å‚™ï¼šMANUSCRIPT_bioRxiv_SUBMISSION_FINAL.pdfï¼‰
- [x] æ‰€æœ‰ä½œè€…åŒæ„æŠ•ç¨¿
- [x] æ–‡ç« æœªåœ¨å…¶ä»–åœ°æ–¹ç™¼è¡¨
- [x] è³‡é‡‘ä¾†æºè³‡è¨Šï¼ˆå¦‚æœ‰ï¼‰
- [x] åˆ©ç›Šè¡çªè²æ˜ï¼ˆç„¡ï¼‰
- [x] ORCID IDï¼ˆå»ºè­°æä¾›ï¼‰

### âœ… æª”æ¡ˆæ ¼å¼ç¢ºèª
- [x] PDF æ ¼å¼ âœ“
- [x] æª”æ¡ˆå¤§å° < 40 MB âœ“ (2.7 MB)
- [x] æ‰€æœ‰åœ–è¡¨åµŒå…¥ âœ“
- [x] å­—é«”åµŒå…¥ï¼ˆTimes New Romanï¼‰âœ“
- [x] ç„¡ç‰¹æ®Šå­—å…ƒéŒ¯èª¤ âœ“

---

## ğŸ“ æŠ•ç¨¿è¡¨å–®å¡«å¯«æŒ‡å—

### 1. **Article Typeï¼ˆæ–‡ç« é¡å‹ï¼‰**

**å•é¡Œ**: é¸æ“‡ä½ çš„æ–‡ç« é¡å‹

**é¸é …**:
- New Resultsï¼ˆæ–°ç™¼ç¾ï¼‰
- Confirmatory Resultsï¼ˆç¢ºèªæ€§çµæœï¼‰
- Contradictory Resultsï¼ˆçŸ›ç›¾æ€§çµæœï¼‰

**âœ… å»ºè­°é¸æ“‡**: **New Results**

**ç†ç”±**:
- ä½ çš„ç ”ç©¶æå‡ºäº†**å‰µæ–°çš„å¤šç¶­æ•´åˆè¨ˆç®—æ¡†æ¶**
- é¦–æ¬¡ç³»çµ±æ€§åˆ†æ PD-L1 èˆ‡ LLPS è›‹ç™½çš„èª¿æ§ç¶²çµ¡
- åœ¨ 1,635 å€‹ç™Œç—‡æ¨£æœ¬ä¸­ç™¼ç¾æ–°çš„ç”Ÿç‰©å­¸æ´è¦‹
- CMTM6-PD-L1 ç›¸é—œæ€§çš„å…ç–«ç¨ç«‹æ©Ÿåˆ¶æ˜¯æ–°ç™¼ç¾
- éƒ¨åˆ†ç›¸é—œåˆ†æï¼ˆæ§åˆ¶å…ç–«å› å­ï¼‰æ˜¯æ–¹æ³•å­¸å‰µæ–°

**å¦‚ä½•å›ç­”**:
> "This study presents **new computational and biological findings** regarding PD-L1 regulatory mechanisms. Our multi-dimensional integrative framework reveals novel immune-independent coordination between CMTM6 and PD-L1, advancing understanding of checkpoint regulation beyond traditional immune-centric models."

---

### 2. **Subject Categoryï¼ˆå­¸ç§‘åˆ†é¡ï¼‰**

**å•é¡Œ**: é¸æ“‡ä¸€å€‹æœ€ç›¸é—œçš„å­¸ç§‘åˆ†é¡ï¼ˆåªèƒ½é¸ä¸€å€‹ï¼‰

**ä¸»è¦é¸é …**:
- **Bioinformatics** (38,084 ç¯‡æ–‡ç« )
- **Cancer Biology** (16,772 ç¯‡æ–‡ç« )
- Systems Biology
- Genomics
- Immunology

**âœ… å»ºè­°é¸æ“‡**: **Cancer Biology**

**ç†ç”±**:
1. **ä¸»è¦è²¢ç»æ˜¯ç™Œç—‡ç”Ÿç‰©å­¸æ´è¦‹**ï¼Œè€Œéç´”ç²¹æ–¹æ³•å­¸
2. ç ”ç©¶ç„¦é»æ˜¯ **PD-L1 èª¿æ§æ©Ÿåˆ¶åœ¨ç™Œç—‡ä¸­çš„ä½œç”¨**
3. è‡¨åºŠç›¸é—œæ€§å¼·ï¼ˆå…ç–«æª¢æŸ¥é»æ²»ç™‚ï¼‰
4. é›–ç„¶ä½¿ç”¨è¨ˆç®—æ–¹æ³•ï¼Œä½†**ç”Ÿç‰©å­¸å•é¡Œå°å‘**
5. Cancer Biology è®€è€…ç¾¤æ›´ç›´æ¥ç›¸é—œæ–¼å…ç–«æ²»ç™‚ç ”ç©¶

**æ›¿ä»£é¸æ“‡**: Bioinformaticsï¼ˆå¦‚æœå¯©ç¨¿ç·¨è¼¯å»ºè­°æ›´æ”¹ï¼‰

**å¦‚ä½•å‘ç·¨è¼¯èªªæ˜**:
> "While this study employs advanced computational methods, the **primary contribution is biological insight** into PD-L1 regulatory networks in cancer. The findings have direct implications for **checkpoint immunotherapy** and cancer treatment, making Cancer Biology the most appropriate category for reaching our target audience."

---

### 3. **Titleï¼ˆæ¨™é¡Œï¼‰**

**âœ… ä½¿ç”¨ç¾æœ‰æ¨™é¡Œ**:
```
Multi-Dimensional Integrative Analysis of PD-L1 Regulatory Networks: A Computational Framework Integrating Large-Scale Genomics and Immune Deconvolution Across 1,635 Cancer Patients
```

**å„ªé»**:
- æ¸…æ¥šèªªæ˜ç ”ç©¶å…§å®¹ï¼ˆMulti-Dimensional Integrative Analysisï¼‰
- åŒ…å«é—œéµå­—ï¼ˆPD-L1, Regulatory Networks, Genomics, Immune Deconvolutionï¼‰
- å¼·èª¿æ¨£æœ¬é‡ï¼ˆ1,635 patientsï¼‰å¢åŠ å¯ä¿¡åº¦
- èªªæ˜æ–¹æ³•ï¼ˆComputational Frameworkï¼‰

**æ˜¯å¦éœ€è¦ä¿®æ”¹**: **ä¸éœ€è¦**ï¼ˆå·²ç¶“å¾ˆå¥½ï¼‰

---

### 4. **Authorsï¼ˆä½œè€…è³‡è¨Šï¼‰**

**å•é¡Œ**: æä¾›æ‰€æœ‰ä½œè€…çš„è©³ç´°è³‡è¨Š

**âœ… å»ºè­°å¡«å¯«**:

**é€šè¨Šä½œè€…ï¼ˆCorresponding Authorï¼‰**:
- **å§“å**: Hsiu-Chi Tsai
- **æ©Ÿæ§‹**: [å¡«å¯«ä½ çš„æ©Ÿæ§‹å…¨å]
- **Email**: [ä½ çš„å°ˆæ¥­ email]
- **ORCID**: [å¼·çƒˆå»ºè­°æä¾›ï¼Œå¦‚æœæ²’æœ‰è«‹ç«‹å³è¨»å†Šï¼šhttps://orcid.org/]

**ä½œè€…è²¢ç»è²æ˜ç¯„ä¾‹**:
> "H-CT designed the study, performed all analyses, interpreted the results, and wrote the manuscript."

**âš ï¸ é‡è¦**:
- ç¢ºä¿æ‰€æœ‰å…±åŒä½œè€…ï¼ˆå¦‚æœ‰ï¼‰éƒ½**åŒæ„æŠ•ç¨¿**
- æä¾›æº–ç¢ºçš„æ©Ÿæ§‹åç¨±ï¼ˆä½¿ç”¨ ROR ID å¦‚æœå¯èƒ½ï¼‰
- Email å¿…é ˆæ˜¯å¯è¯ç¹«çš„å°ˆæ¥­ä¿¡ç®±

---

### 5. **Abstractï¼ˆæ‘˜è¦ï¼‰**

**å•é¡Œ**: æä¾›æ‘˜è¦ï¼ˆé€šå¸¸æœƒå¾ PDF ä¸­è‡ªå‹•æå–ï¼‰

**âœ… ç¢ºèªè¦é»**:
- [x] èƒŒæ™¯æ¸…æ¥šï¼ˆPD-L1 åœ¨å…ç–«æ²»ç™‚ä¸­çš„é‡è¦æ€§ï¼‰
- [x] æ–¹æ³•æ˜ç¢ºï¼ˆ1,635 æ¨£æœ¬ï¼Œå¤šç¶­åˆ†æï¼‰
- [x] çµæœå…·é«”ï¼ˆCMTM6 Ï=0.42, 74% immune-independentï¼‰
- [x] çµè«–æœ‰åŠ›ï¼ˆrobust, validated findingsï¼‰

**æ˜¯å¦éœ€è¦ä¿®æ”¹**: ä½ çš„æ‘˜è¦å·²ç¶“éå¸¸å®Œæ•´ï¼Œ**ä¸éœ€è¦ä¿®æ”¹**

---

### 6. **Keywordsï¼ˆé—œéµå­—ï¼‰**

**å•é¡Œ**: æä¾› 5-10 å€‹é—œéµå­—

**âœ… å»ºè­°é—œéµå­—**ï¼ˆæŒ‰é‡è¦æ€§æ’åºï¼‰:
1. PD-L1
2. Checkpoint immunotherapy
3. CMTM6
4. Liquid-liquid phase separation
5. Immune microenvironment
6. TCGA
7. Partial correlation
8. Survival analysis
9. Cancer genomics
10. TIMER2.0

**å¦‚ä½•é¸æ“‡é—œéµå­—**:
- åŒ…å«ä¸»è¦è›‹ç™½åç¨±ï¼ˆPD-L1, CMTM6, STUB1ï¼‰
- åŒ…å«ç ”ç©¶æ–¹æ³•ï¼ˆpartial correlation, survival analysisï¼‰
- åŒ…å«ç ”ç©¶é ˜åŸŸï¼ˆimmunotherapy, cancer genomicsï¼‰
- åŒ…å«æ•¸æ“šä¾†æºï¼ˆTCGA, TIMER2.0ï¼‰
- é¿å…éæ–¼å»£æ³›çš„è©ï¼ˆå¦‚ "cancer", "biology"ï¼‰

---

### 7. **Fundingï¼ˆè³‡é‡‘ä¾†æºï¼‰**

**å•é¡Œ**: åˆ—å‡ºæ‰€æœ‰è³‡åŠ©ä¾†æº

**é¸é … A**: å¦‚æœæœ‰è³‡åŠ©
```
æä¾›:
- è³‡åŠ©æ©Ÿæ§‹åç¨±ï¼ˆä½¿ç”¨ ROR IDï¼‰
- Grant numberï¼ˆè³‡åŠ©ç·¨è™Ÿï¼‰
- ä¸»æŒäººå§“å
```

**é¸é … B**: å¦‚æœç„¡è³‡åŠ©

**âœ… å»ºè­°å›ç­”**:
```
No external funding was received for this research.
```

**âš ï¸ é‡è¦**: å¦‚å¯¦å¡«å¯«ï¼Œé€™é—œä¿‚åˆ°é€æ˜åº¦å’Œå€«ç†

---

### 8. **Conflict of Interestï¼ˆåˆ©ç›Šè¡çªï¼‰**

**å•é¡Œ**: æ˜¯å¦å­˜åœ¨åˆ©ç›Šè¡çªï¼Ÿ

**âœ… å»ºè­°å›ç­”**:
```
The author declares no competing interests.
```

**âš ï¸ å¦‚æœæœ‰ä»»ä½•å¯èƒ½çš„åˆ©ç›Šè¡çª**ï¼ˆä¾‹å¦‚ï¼šèˆ‡è£½è—¥å…¬å¸åˆä½œã€æŒæœ‰å°ˆåˆ©ç­‰ï¼‰ï¼Œå¿…é ˆè²æ˜ï¼š
```
The author declares the following potential conflict of interest: [å…·é«”èªªæ˜]
```

---

### 9. **Licenseï¼ˆç‰ˆæ¬Šè¨±å¯ï¼‰**

**å•é¡Œ**: é¸æ“‡æ–‡ç« çš„ä½¿ç”¨è¨±å¯

**é¸é …**:
1. **CC BY** (Creative Commons Attribution) - æœ€é–‹æ”¾
2. **CC BY-NC** (Non-Commercial) - ä¸å…è¨±å•†æ¥­ä½¿ç”¨
3. **CC BY-ND** (No Derivatives) - ä¸å…è¨±æ”¹ä½œ
4. **CC BY-NC-ND** - æœ€åš´æ ¼
5. **CC0** (Public Domain) - å®Œå…¨æ”¾æ£„ç‰ˆæ¬Š
6. **No reuse** - ä¿ç•™æ‰€æœ‰æ¬Šåˆ©

**âœ… å»ºè­°é¸æ“‡**: **CC BY 4.0**

**ç†ç”±**:
1. **æœ€å¤§åŒ–å½±éŸ¿åŠ›** - å…è¨±ä»–äººè‡ªç”±ä½¿ç”¨å’Œå¼•ç”¨
2. **ç¬¦åˆé–‹æ”¾ç§‘å­¸ç²¾ç¥** - bioRxiv é¼“å‹µé–‹æ”¾å­˜å–
3. **æœŸåˆŠæ¥å—åº¦é«˜** - å¤§å¤šæ•¸æœŸåˆŠæ¥å— CC BY æˆæ¬Šçš„é å°æœ¬
4. **å¼•ç”¨ç‡æ›´é«˜** - é–‹æ”¾å­˜å–æ–‡ç« å¹³å‡å¼•ç”¨ç‡è¼ƒé«˜
5. **ä½ ä»ä¿æœ‰ç‰ˆæ¬Š** - åªæ˜¯æˆæ¬Šä»–äººä½¿ç”¨ï¼Œéœ€è¨»æ˜å‡ºè™•

**å¦‚ä½•èªªæ˜**:
> "I choose CC BY 4.0 to maximize the impact and accessibility of this research, in line with open science principles."

**âš ï¸ æ³¨æ„**: å¦‚æœæœªä¾†è¦æŠ•ç¨¿åˆ°æŸäº›æœŸåˆŠï¼Œè«‹å…ˆç¢ºèªè©²æœŸåˆŠçš„é å°æœ¬æ”¿ç­–

---

### 10. **Data and Code Availabilityï¼ˆè³‡æ–™èˆ‡ç¨‹å¼ç¢¼å¯ç”¨æ€§ï¼‰**

**å•é¡Œ**: è³‡æ–™å’Œç¨‹å¼ç¢¼æ˜¯å¦å…¬é–‹ï¼Ÿ

**âœ… å»ºè­°å›ç­”**:

**è³‡æ–™ä¾†æºè²æ˜**:
```
All data used in this study are publicly available:
- TCGA RNA-seq data: GDC Data Portal (https://portal.gdc.cancer.gov/)
- Immune deconvolution: TIMER2.0 (http://timer.cistrome.org/)
- Sample size: 1,635 patients across LUAD, LUSC, and SKCM cohorts
```

**ç¨‹å¼ç¢¼è²æ˜**ï¼ˆå¦‚æœä½ é¡˜æ„åˆ†äº«ï¼‰:
```
Analysis code and computational pipeline are available upon request from the corresponding author.
```

**æˆ–è€…æ›´å¥½**ï¼ˆå¼·çƒˆå»ºè­°ï¼‰:
```
Analysis code is available at: [GitHub repository URL]
```

**âš ï¸ ç‚ºäº†æé«˜å¯ä¿¡åº¦å’Œå¼•ç”¨ç‡**:
- è€ƒæ…®å°‡ç¨‹å¼ç¢¼ä¸Šå‚³åˆ° GitHub
- ä½¿ç”¨ Zenodo ç²å¾— DOI
- åœ¨æ–‡ç« ä¸­æä¾› GitHub é€£çµ

---

### 11. **Ethics Statementï¼ˆå€«ç†è²æ˜ï¼‰**

**å•é¡Œ**: ç ”ç©¶æ˜¯å¦æ¶‰åŠäººé«”æ¨£æœ¬æˆ–å‹•ç‰©å¯¦é©—ï¼Ÿ

**âœ… å»ºè­°å›ç­”**:
```
This study exclusively uses publicly available de-identified data from The Cancer Genome Atlas (TCGA). All original TCGA data collection was performed in accordance with institutional review board approvals and informed consent from all participants as described in the original TCGA publications. No additional ethical approval was required for this secondary analysis of publicly available data.
```

**é—œéµé»**:
- å¼·èª¿ä½¿ç”¨**å…¬é–‹å»è­˜åˆ¥åŒ–æ•¸æ“š**
- æŒ‡å‡ºåŸå§‹ TCGA ç ”ç©¶å·²ç²å¾—å€«ç†æ‰¹å‡†
- èªªæ˜é€™æ˜¯**äºŒæ¬¡åˆ†æ**ï¼Œä¸éœ€è¦é¡å¤–æ‰¹å‡†

---

### 12. **Cover Letterï¼ˆæŠ•ç¨¿ä¿¡ï¼‰** (å¯é¸ä½†å»ºè­°æä¾›)

**å•é¡Œ**: ç‚ºä»€éº¼é€™é …ç ”ç©¶é‡è¦ï¼Ÿç‚ºä»€éº¼é©åˆ bioRxivï¼Ÿ

**âœ… å»ºè­°å…§å®¹**:

```markdown
Dear bioRxiv Editorial Team,

I am pleased to submit our manuscript entitled "Multi-Dimensional Integrative Analysis of PD-L1 Regulatory Networks: A Computational Framework Integrating Large-Scale Genomics and Immune Deconvolution Across 1,635 Cancer Patients" for posting as a preprint on bioRxiv.

## Why This Work is Important

PD-L1 checkpoint immunotherapy has revolutionized cancer treatment, yet our understanding of its regulatory mechanisms remains incomplete. This study addresses critical gaps by:

1. **Revealing immune-independent regulatory mechanisms**: We demonstrate that 74% of the CMTM6-PD-L1 coordination persists after controlling for immune cell infiltration, suggesting intrinsic regulatory mechanisms beyond immune-mediated effects.

2. **Integrating multi-dimensional validation**: Through cancer type stratification, outlier exclusion, bootstrap resampling (1,000 iterations), and alternative statistical methods, we achieve >95% directional consistency across all sensitivity analyses.

3. **Providing a generalizable computational framework**: Our integrative pipeline combining large-scale genomics (TCGA, n=1,635) and immune deconvolution (TIMER2.0) offers a template for studying other checkpoint regulators.

## Significance and Novelty

- **Largest systematic analysis** of PD-L1 regulatory networks across multiple cancer types
- **Novel biological insight**: Immune-independent CMTM6-PD-L1 coordination mechanism
- **Robust methodology**: Comprehensive sensitivity analyses ensure findings are not artifacts
- **Clinical relevance**: Direct implications for checkpoint immunotherapy strategies

## Why bioRxiv

We choose bioRxiv to:
- Share our findings rapidly with the cancer immunotherapy community
- Receive early feedback before journal submission
- Establish priority for our computational framework and biological discoveries
- Support open science and reproducible research

All data are publicly available (TCGA, TIMER2.0), and we commit to sharing our analysis code upon request to ensure full reproducibility.

Thank you for considering our manuscript. I look forward to making this work available to the broader scientific community through bioRxiv.

Sincerely,
Hsiu-Chi Tsai
[Your Institution]
[Your Email]
```

---

## ğŸ¯ æé«˜éŒ„å–æ©Ÿæœƒçš„é—œéµç­–ç•¥

### 1. **æ–‡ç« å“è³ªæ˜¯é—œéµ**
bioRxiv çš„ç¯©é¸ä¸»è¦é‡å°ä»¥ä¸‹æ–¹é¢ï¼š
- âœ… **ç§‘å­¸å…§å®¹å®Œæ•´** - ä½ çš„æ–‡ç« å·²ç¶“éå¸¸å®Œæ•´
- âœ… **éæŠ„è¥²** - ç¢ºä¿æ‰€æœ‰å…§å®¹æ˜¯åŸå‰µçš„
- âœ… **é©ç•¶çš„æ–‡ç« é¡å‹** - é€™æ˜¯ç ”ç©¶è«–æ–‡ï¼Œç¬¦åˆè¦æ±‚
- âœ… **ç„¡å¥åº·å±å®³å…§å®¹** - ä¸æ¶‰åŠ

### 2. **æŠ€è¡“æ ¼å¼æ­£ç¢º**
- âœ… PDF æ ¼å¼æ­£ç¢º
- âœ… æ‰€æœ‰åœ–è¡¨åµŒå…¥
- âœ… å­—é«”æ­£ç¢ºï¼ˆTimes New Romanï¼‰
- âœ… ç„¡ç‰¹æ®Šå­—å…ƒéŒ¯èª¤
- âœ… ä½œè€…è³‡è¨Šå®Œæ•´

### 3. **æä¾›å®Œæ•´è³‡è¨Š**
- âœ… æº–ç¢ºçš„ä½œè€…è³‡è¨Šå’Œæ©Ÿæ§‹
- âœ… ORCID IDï¼ˆå¼·çƒˆå»ºè­°ï¼‰
- âœ… è³‡é‡‘ä¾†æºè²æ˜
- âœ… è³‡æ–™å¯ç”¨æ€§è²æ˜
- âœ… å€«ç†è²æ˜

### 4. **é¸æ“‡é©ç•¶åˆ†é¡**
- âœ… Subject category: **Cancer Biology**ï¼ˆæœ€ç›¸é—œè®€è€…ç¾¤ï¼‰
- âœ… Article type: **New Results**ï¼ˆå¼·èª¿å‰µæ–°æ€§ï¼‰

### 5. **é–‹æ”¾å­˜å–**
- âœ… é¸æ“‡ **CC BY 4.0** è¨±å¯ï¼ˆæœ€å¤§åŒ–å½±éŸ¿åŠ›ï¼‰
- âœ… è²æ˜è³‡æ–™å…¬é–‹å¯å¾—

---

## â° æŠ•ç¨¿æµç¨‹æ™‚é–“ç·š

### æŠ•ç¨¿ç•¶å¤©
1. ç·šä¸Šè¨»å†Šå¸³è™Ÿï¼ˆå¦‚æœå°šæœªè¨»å†Šï¼‰
2. å¡«å¯«æŠ•ç¨¿è¡¨å–®ï¼ˆ30-45 åˆ†é˜ï¼‰
3. ä¸Šå‚³ PDF æª”æ¡ˆ
4. æª¢æŸ¥ä¸¦æäº¤

### 24-48 å°æ™‚å…§
- bioRxiv å…§éƒ¨ç¯©é¸ï¼ˆæª¢æŸ¥æ ¼å¼ã€ä½œè€…è³‡è¨Šã€ç‰¹æ®Šå­—å…ƒç­‰ï¼‰

### 48-72 å°æ™‚å…§
- ç§‘å­¸ç¯©é¸ï¼ˆæª¢æŸ¥æŠ„è¥²ã€ç§‘å­¸å…§å®¹é©ç•¶æ€§ï¼‰

### ç´„ 1 é€±å…§
- **æ–‡ç« ä¸Šç·šç™¼å¸ƒ** ğŸ‰
- ç²å¾— DOI
- å¯ä»¥å¼•ç”¨

### ä¸Šç·šå¾Œ
- å¯ä»¥åœ¨ Twitter/ç¤¾äº¤åª’é«”åˆ†äº«
- å¯ä»¥æŠ•ç¨¿åˆ°æ­£å¼æœŸåˆŠï¼ˆå¤§å¤šæ•¸æœŸåˆŠæ¥å— bioRxiv é å°æœ¬ï¼‰
- å¦‚æœ‰éœ€è¦å¯ä»¥ä¸Šå‚³ä¿®è¨‚ç‰ˆæœ¬

---

## ğŸ“§ å¯èƒ½çš„å¯©ç¨¿å•é¡Œèˆ‡æ‡‰å°

### å•é¡Œ 1: "ä½œè€…è³‡è¨Šä¸å®Œæ•´"
**æ‡‰å°**: ç¢ºä¿æä¾›å®Œæ•´æ©Ÿæ§‹åç¨±ã€Emailã€ORCID

### å•é¡Œ 2: "åœ–è¡¨æ ¼å¼å•é¡Œ"
**æ‡‰å°**: ä½ çš„ PDF å·²åŒ…å«æ‰€æœ‰åœ–è¡¨ï¼Œæ‡‰è©²ä¸æœƒæœ‰å•é¡Œ

### å•é¡Œ 3: "éœ€è¦æ›´å¤šè³‡æ–™å¯ç”¨æ€§è³‡è¨Š"
**æ‡‰å°**: åœ¨ submission form ä¸­æ˜ç¢ºèªªæ˜ä½¿ç”¨ TCGA å’Œ TIMER2.0 å…¬é–‹è³‡æ–™

### å•é¡Œ 4: "Subject category ä¸ç¢ºå®š"
**æ‡‰å°**: å¯ä»¥åœ¨ cover letter ä¸­èªªæ˜ç‚ºä»€éº¼é¸æ“‡ Cancer Biology

---

## âœ… æœ€çµ‚æª¢æŸ¥æ¸…å–®ï¼ˆæŠ•ç¨¿å‰ï¼‰

æŠ•ç¨¿å‰è«‹ç¢ºèªä»¥ä¸‹æ‰€æœ‰é …ç›®ï¼š

- [ ] PDF æª”æ¡ˆå·²æº–å‚™å¥½ï¼ˆMANUSCRIPT_bioRxiv_SUBMISSION_FINAL.pdfï¼‰
- [ ] å·²è¨»å†Š bioRxiv å¸³è™Ÿ
- [ ] å·²æº–å‚™ ORCID ID
- [ ] å·²ç¢ºèªæ‰€æœ‰ä½œè€…åŒæ„æŠ•ç¨¿
- [ ] å·²æº–å‚™å®Œæ•´çš„ä½œè€…è³‡è¨Šå’Œæ©Ÿæ§‹åç¨±
- [ ] å·²æ±ºå®š Subject Category: **Cancer Biology**
- [ ] å·²æ±ºå®š Article Type: **New Results**
- [ ] å·²æ±ºå®š License: **CC BY 4.0**
- [ ] å·²æº–å‚™ Funding statement
- [ ] å·²æº–å‚™ Conflict of Interest statement
- [ ] å·²æº–å‚™ Data Availability statement
- [ ] å·²æº–å‚™ Ethics statement
- [ ] å·²æº–å‚™ Cover Letterï¼ˆå¯é¸ä½†å»ºè­°ï¼‰
- [ ] å·²æº–å‚™ Keywords (10 å€‹)

---

## ğŸ‰ æŠ•ç¨¿å¾Œä¸‹ä¸€æ­¥

### ç«‹å³è¡Œå‹•
1. **ä¿å­˜æŠ•ç¨¿ç¢ºèª Email**
2. **è¨˜éŒ„æŠ•ç¨¿ç·¨è™Ÿ**
3. **æº–å‚™ç¤¾äº¤åª’é«”å®£å‚³å…§å®¹**ï¼ˆæ–‡ç« ä¸Šç·šå¾Œä½¿ç”¨ï¼‰

### æ–‡ç« ä¸Šç·šå¾Œ
1. **ç²å¾— DOI** - æ°¸ä¹…å¼•ç”¨é€£çµ
2. **åˆ†äº«åˆ°ç¤¾äº¤åª’é«”**ï¼ˆTwitter, LinkedIn, ResearchGateï¼‰
3. **é€šçŸ¥ç›¸é—œç ”ç©¶è€…**
4. **æº–å‚™æŠ•ç¨¿åˆ°æ­£å¼æœŸåˆŠ**

### æœŸåˆŠæŠ•ç¨¿é¸æ“‡ï¼ˆbioRxiv ä¸Šç·šå¾Œï¼‰
æ ¹æ“šä½ çš„ç ”ç©¶é ˜åŸŸï¼Œå¯è€ƒæ…®æŠ•ç¨¿åˆ°ï¼š
- **Nature Communications** - é«˜å½±éŸ¿åŠ›ï¼Œé–‹æ”¾å­˜å–
- **Cancer Research** - ç™Œç—‡ç ”ç©¶é ‚ç´šæœŸåˆŠ
- **Clinical Cancer Research** - è‡¨åºŠç›¸é—œæ€§å¼·
- **JCI Insight** - æ©Ÿåˆ¶ç ”ç©¶
- **Frontiers in Immunology** - å…ç–«å­¸ç„¦é»
- **BMC Cancer** - é–‹æ”¾å­˜å–
- **PLOS Computational Biology** - å¦‚æœå¼·èª¿è¨ˆç®—æ–¹æ³•

---

## ğŸ“ éœ€è¦å¹«åŠ©ï¼Ÿ

**bioRxiv æ”¯æ´ Email**: [email protected]

**å¸¸è¦‹å•é¡Œ**: https://www.biorxiv.org/about/FAQ

---

## ğŸš€ æº–å‚™æŠ•ç¨¿ï¼

ä½ çš„è«–æ–‡å·²ç¶“æº–å‚™å®Œå–„ï¼š
- âœ… PDF å“è³ªå„ªç§€ï¼ˆ2.7 MB, 34 pagesï¼‰
- âœ… æ‰€æœ‰åœ–è¡¨å°ˆæ¥­ä¸”æ¸…æ™°
- âœ… å…§å®¹å®Œæ•´ä¸”åš´è¬¹
- âœ… æ ¼å¼ç¬¦åˆ bioRxiv è¦æ±‚

**æŠ•ç¨¿ç¶²å€**: https://submit.biorxiv.org/

**é æœŸæ™‚é–“ç·š**:
- æäº¤: ä»Šå¤©
- ç¯©é¸: 24-48 å°æ™‚
- ä¸Šç·š: ç´„ 1 é€±å…§

**ç¥æŠ•ç¨¿é †åˆ©ï¼** ğŸ‰

---

**æœ€å¾Œæ›´æ–°**: 2025-11-07
**æ–‡ä»¶ç‰ˆæœ¬**: 1.0
**æº–å‚™è€…**: Claude Code AI Assistant
